
Sweden’s real-world CAR-T cell therapy data for aggressive B-cell lymphoma (ABCL) and B-acute lymphoblastic leukemia (B-ALL) show promising results. Axi-cel achieved a 66% complete remission rate in ABCL, with a 53% 12-month PFS, while tisa-cel led to 92% remission in B-ALL. Lower toxicity rates than global studies highlight Sweden’s strict patient selection and national collaboration.
Like
Save
Share